Evidence map›Paper›PMID 38607917›Full record

ArticleCell reports2024

SARS-CoV-2 variant of concern fitness and adaptation in primary human airway epithelia.

Rita M Meganck, Caitlin E Edwards, Michael L Mallory, Rhianna E Lee, Hong Dang, Alexis B Bailey, Jason A Wykoff, Samuel C Gallant, Deanna R Zhu, Boyd L Yount and 15 more

Open access · goldAbstract read
In one paragraph

Article in Cell reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 3 institutions in 1 country.

Rita M MeganckDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Caitlin E EdwardsDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Michael L MalloryDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Rhianna E LeeMarsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Hong DangMarsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Alexis B BaileyDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Jason A WykoffMarsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Samuel C GallantMarsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Deanna R ZhuDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Boyd L YountDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Takafumi KatoMarsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Kendall M ShafferMarsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Satoko NakanoMarsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Anne Marie CawleyMarsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Vishwaraj SontakeDepartment of Cell Biology, Duke University, Durham, NC 27710, USA.
Jeremy R WangDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Robert S HaganMarsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA; Division of Pulmonary Diseases and Critical Care Medicine, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Melissa B MillerDepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Purushothama Rao TataDepartment of Cell Biology, Duke University, Durham, NC 27710, USA.
Scott H RandellMarsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Longping V TseDepartment of Molecular Microbiology & Immunology, Saint Louis University, St. Louis, MO 63104, USA.
Camille EhreMarsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Kenichi OkudaMarsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Richard C BoucherMarsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Ralph S BaricDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA. Electronic address: rbaric@email.unc.edu.
University of North Carolina at Chapel Hill · USDuke University · USSaint Louis University · US

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI Laura Fish · 1985 to 2026
$174.8M
Research Project 1: Coronavirus antiviral lead development and combination testingU19AI171292 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARIC, RALPH S, WILLSON, TIMOTHY M · 2022 to 2022
$65.5M
UNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Hazel B Nichols · 2001 to 2026
$36.3M
Vector CoreP30DK065988 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Scott H Randell · 2004 to 2026
$26.5M
The Biophysics of Mucus Hydration and Adhesion/CohesionP01HL108808 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KESIMER, MEHMET · 2012 to 2021
$23.9M
Project 4: Biophysical and structural characterization of airway submucosal gland mucus in health and diseaseP01HL164320 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Richard Charles Boucher, Michael Rubinstein · 2022 to 2026
$13.9M
Stanford/UNC Biomimetic U19 Research CenterU19AI116484 · NIAID · STANFORD UNIVERSITY · PI GREENBERG, HARRY BERNARD · 2015 to 2025
$13.5M
Project 3: Serological Interactions with the Mucosal Innate Immune System Regulates COVID-19 Associated Tissue Damage.U54CA260543 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WOLFGANG, MATTHEW C · 2020 to 2024
$9.8M
Mechanisms of MERS-CoV Entry, Cross-species Transmission and PathogenesisR01AI110700 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARIC, RALPH S, LI, FANG · 2015 to 2024
$7.4M
Molecular control of a novel transitional cell state in alveolar regenerationR01HL153375 · NHLBI · DUKE UNIVERSITY · PI Purushothama Rao Tata · 2020 to 2026
$3.4M
The molecular and cellular mechanisms of the STAT3 mutation-mediated pulmonary disorder in Autosomal Dominant Hyper IgE Syndrome (AD-HIES)U01HL156655 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BOUCHER, RICHARD CHARLES, CHEN, GANG · 2022 to 2025
$3.0M
NCI NIH HHS P30 CA014236NCI NIH HHS P30 CA016086NCI NIH HHS U54 CA260543NHLBI NIH HHS K08 HL143271NHLBI NIH HHS P01 HL108808NHLBI NIH HHS P01 HL164320NHLBI NIH HHS R01 HL146557NHLBI NIH HHS R01 HL153375NHLBI NIH HHS R01 HL160939NHLBI NIH HHS R01 HL163602NHLBI NIH HHS R03 HL155249NHLBI NIH HHS U01 HL156655NIAID NIH HHS R01 AI110700NIAID NIH HHS U19 AI116484NIAID NIH HHS U19 AI171292NIDDK NIH HHS P30 DK065988NIEHS NIH HHS P30 ES010126
6 · The paper itself

Abstract

The severe acute respiratory syndrome coronavirus 2 pandemic is characterized by the emergence of novel variants of concern (VOCs) that replace ancestral strains. Here, we dissect the complex selective pressures by evaluating variant fitness and adaptation in human respiratory tissues. We evaluate viral properties and host responses to reconstruct forces behind D614G through Omicron (BA.1) emergence. We observe differential replication in airway epithelia, differences in cellular tropism, and virus-induced cytotoxicity. D614G accumulates the most mutations after infection, supporting zoonosis and adaptation to the human airway. We perform head-to-head competitions and observe the highest fitness for Gamma and Delta. Under these conditions, RNA recombination favors variants encoding the B.1.617.1 lineage 3' end. Based on viral growth kinetics, Alpha, Gamma, and Delta exhibit increased fitness compared to D614G. In contrast, the global success of Omicron likely derives from increased transmission and antigenic variation. Our data provide molecular evidence to support epidemiological observations of VOC emergence.

Indexed as

COVID-19SARS-CoV-2Adaptation, PhysiologicalAnimalsChlorocebus aethiopsEpithelial CellsGenetic FitnessHumansMutationRespiratory MucosaVero CellsVirus Replicationadaptationcellular tropismcompetitioncoronavirusCP: Microbiologyprimary airway culturerecombinationSARS-CoV-2single cell RNA-seqvariants of concernviral fitness

Identifiers

PMID38607917
PMCPMC11165423
OpenAlexW4394694607

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.